Clonal Somatic Copy Number Altered Driver Events Inform Drug Sensitivity in High-grade Serous Ovarian Cancer

Chromosomal instability is a major challenge to patient stratification and targeted drug development for high-grade serous ovarian carcinoma (HGSOC). Here we show that somatic copy number alterations (SCNAs) in frequently amplified HGSOC cancer genes significantly correlate with gene expression and methylation status. We identify five prevalent clonal driver SCNAs (chromosomal amplifications encompassing MYC, PIK3CA, CCNE1, KRAS and TERT) from multi-regional HGSOC data and reason that their strong selection should prioritise them as key biomarkers for targeted therapies. We use primary HGSOC spheroid models to test interactions between in vitro targeted therapy and SCNAs. MYC chromosomal copy number is associated with in-vitro and clinical response to paclitaxel and in-vitro response to mTORC1/2 inhibition. Activation of the mTOR survival pathway in the context of MYC-amplified HGSOC is statistically associated with increased prevalence of SCNAs in genes from the PI3K pathway. Co-occurrence of amplifications in MYC and genes from the PI3K pathway is independently observed in squamous lung cancer and triple negative breast cancer. In this work, we show that identifying co-occurrence of clonal driver SCNA genes could be used to tailor therapeutics for precision medicine.

Citing Articles

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.

Wei J, Li W, Zhang P, Guo F, Liu M Mol Cancer. 2024; 23(1):279.

PMID: 39725966 PMC: 11670468. DOI: 10.1186/s12943-024-02179-5.

Outani H, Ikegami M, Imura Y, Nakai S, Takami H, Kotani Y Int J Clin Oncol. 2024; 30(2):397-406.

PMID: 39688743 PMC: 11785636. DOI: 10.1007/s10147-024-02673-2.

The Role of Circulating Tumor DNA in Ovarian Cancer.

Golara A, Kozlowski M, Cymbaluk-Ploska A Cancers (Basel). 2024; 16(18).

PMID: 39335089 PMC: 11430586. DOI: 10.3390/cancers16183117.

Ecological and evolutionary dynamics to design and improve ovarian cancer treatment.

Han G, Alexander M, Gattozzi J, Day M, Kirsch E, Tafreshi N Clin Transl Med. 2024; 14(9):e70012.

PMID: 39210542 PMC: 11362027. DOI: 10.1002/ctm2.70012.

Single nucleotide and copy number variants of cancer driver genes inform drug response in multiple cancers.

Wang Z, Gu H, Qin P, Wang J PLoS One. 2024; 19(7):e0306343.

PMID: 39083502 PMC: 11290640. DOI: 10.1371/journal.pone.0306343.

References

Harrington E, Bennett M, Fanidi A, Evan G . c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J. 1994; 13(14):3286-95. PMC: 395225. DOI: 10.1002/j.1460-2075.1994.tb06630.x. View

Bhattacharya A, Bense R, Urzua-Traslavina C, de Vries E, van Vugt M, Fehrmann R . Transcriptional effects of copy number alterations in a large set of human cancers. Nat Commun. 2020; 11(1):715. PMC: 7002723. DOI: 10.1038/s41467-020-14605-5. View

Spector N, Xia W, Burris 3rd H, Hurwitz H, Dees E, Dowlati A . Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005; 23(11):2502-12. DOI: 10.1200/JCO.2005.12.157. View

Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

Reyes-Gonzalez J, Armaiz-Pena G, Mangala L, Valiyeva F, Ivan C, Pradeep S . Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015; 14(10):2260-9. PMC: 4596776. DOI: 10.1158/1535-7163.MCT-14-0801. View

Ciriello G, Miller M, Aksoy B, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10):1127-33. PMC: 4320046. DOI: 10.1038/ng.2762. View

Macintyre G, Goranova T, De Silva D, Ennis D, Piskorz A, Eldridge M . Copy number signatures and mutational processes in ovarian carcinoma. Nat Genet. 2018; 50(9):1262-1270. PMC: 6130818. DOI: 10.1038/s41588-018-0179-8. View

Etemadmoghadam D, Weir B, Au-Yeung G, Alsop K, Mitchell G, George J . Synthetic lethality between CCNE1 amplification and loss of BRCA1. Proc Natl Acad Sci U S A. 2013; 110(48):19489-94. PMC: 3845173. DOI: 10.1073/pnas.1314302110. View

Tamborero D, Dienstmann R, Rachid M, Boekel J, Baird R, Brana I . Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal. Nat Med. 2020; 26(7):992-994. DOI: 10.1038/s41591-020-0969-2. View

10.

Flinn E, Busch C, Wright A . myc boxes, which are conserved in myc family proteins, are signals for protein degradation via the proteasome. Mol Cell Biol. 1998; 18(10):5961-9. PMC: 109182. DOI: 10.1128/MCB.18.10.5961. View

11.

Dogan F, Biray Avci C . Correlation between telomerase and mTOR pathway in cancer stem cells. Gene. 2017; 641:235-239. DOI: 10.1016/j.gene.2017.09.072. View

12.

Verhaak R, Tamayo P, Yang J, Hubbard D, Zhang H, Creighton C . Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2012; 123(1):517-25. PMC: 3533304. DOI: 10.1172/JCI65833. View

13.

Hanrahan A, Schultz N, Westfal M, Sakr R, Giri D, Scarperi S . Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov. 2012; 2(1):56-67. PMC: 3274821. DOI: 10.1158/2159-8290.CD-11-0170. View

14.

Shukla A, Nguyen T, Moka S, Ellis J, Grady J, Oey H . Chromosome arm aneuploidies shape tumour evolution and drug response. Nat Commun. 2020; 11(1):449. PMC: 6978319. DOI: 10.1038/s41467-020-14286-0. View

15.

Sarid J, Halazonetis T, Murphy W, Leder P . Evolutionarily conserved regions of the human c-myc protein can be uncoupled from transforming activity. Proc Natl Acad Sci U S A. 1987; 84(1):170-3. PMC: 304164. DOI: 10.1073/pnas.84.1.170. View

16.

Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

17.

Steckel M, Molina-Arcas M, Weigelt B, Marani M, Warne P, Kuznetsov H . Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 2012; 22(8):1227-45. PMC: 3411175. DOI: 10.1038/cr.2012.82. View

18.

Yap T, Kristeleit R, Michalarea V, Pettitt S, Lim J, Carreira S . Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers. Cancer Discov. 2020; 10(10):1528-1543. PMC: 7611385. DOI: 10.1158/2159-8290.CD-20-0163. View

19.

Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R . Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Ann Oncol. 2018; 29(9):1918-1925. PMC: 6158767. DOI: 10.1093/annonc/mdy245. View

20.

Topham C, Tighe A, Ly P, Bennett A, Sloss O, Nelson L . MYC Is a Major Determinant of Mitotic Cell Fate. Cancer Cell. 2015; 28(1):129-40. PMC: 4518499. DOI: 10.1016/j.ccell.2015.06.001. View